87600-98-4

Basic information

• Product Name: 4,6-dichloropyrimidine-5-carboxylic acid
• Synonyms: 5-Carboxy-4,6-dichloropyrimidine, 5-Carboxy-4,6-dichloro-1,3-diazine;4,6-dichloro-5-pyrimidinecarboxylic;4,6-dichloropyrimidine-5-carboxylic acid;4,6-Dichloro-5-pyrimidinecarboxylic acid;5-Carboxy-4,6-dichloropyrimidine;4,6-Dichloro-pyriMidine-5-carboxylic acid 98%;4,6-DichloropyriMidin-5-carboxylic acid;4,6-Dichloropyrimidine-5-Carboxylic Acid(WX614308)
• CAS NO: 87600-98-4
• Molecular Formula: C5H2Cl2N2O2
• Molecular Weight: 192.99
• EINECS: 1308068-626-2
• Product Categories: YY;Carboxylic Acids;Pyrazines, Pyrimidines & Pyridazines;Heterocycle-Pyrimidine series
• Mol File: 87600-98-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 353.8 °C at 760 mmHg
• Flash Point: 167.8 °C
• Appearance: Off-white/Solid
• Density: 1.718 g/cm³
• Vapor Pressure: 1.29E-05mmHg at 25°C
• Refractive Index: 1.614
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -0.03±0.25(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 4,6-dichloropyrimidine-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dichloropyrimidine-5-carboxylic acid(87600-98-4)
• EPA Substance Registry System: 4,6-dichloropyrimidine-5-carboxylic acid(87600-98-4)

Safety Data

• Hazardous Substances Data: 87600-98-4(Hazardous Substances Data)

Usage

Uses

4,6-Dichloropyrimidine-5-carboxylic acid is used as a intermediate for pharmaceutical.

InChI:InChI=1/C5H2Cl2N2O2/c6-3-2(5(10)11)4(7)9-1-8-3/h1H,(H,10,11)

Upstream product

• 5305-40-8 2,6-dichloro-pyrimidine carbaldehyde 

Downstream Products

• 87600-71-3 4,6-dichloro-5-pyrimidinecarboxylic acid methyl ester 

Relevant articles and documents

4-Aminopyrimidine compound, and preparation method and medicinal use thereof

The invention belongs to the field of medicines, and concretely relates to a 4-aminopyrimidine compound having a structural represented by formula (I), or pharmaceutically acceptable salts thereof, a preparation method of the compound, and a use of the compound and the salts as a Bruton tyrosine kinase (BTK) inhibitor. A result of experiments shows that the compound has a significant inhibition effect on the BTK, and can be used for treating thromboembolism, inflammatory disorders, autoimmune diseases, Waldenstrom macroglobulinemia, B cell lymphomas and other diseases.

Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor γ (PPARγ) partial agonists with comparable antidiabetic efficacy to rosiglitazone

A series of novel 2,4,6-trisubstitutedpyrimidine-5-carboxylic acid derivatives were designed and synthesized with the intent of producing a peroxisome proliferator-activated receptor γ (PPARγ) partial agonist for antidiabetic agents. A pharmacophore-driven approach of in-house screening identified compound 7, which led to the identification of compound 9 featuring a 2,4,6-trisubstituted pyrimidine-5-carboxylic acid core. Structure-activity relationship studies of 9 resulted in identifying 4,6-bisbenzylthio-2- methylthiopyrimidine-5-carboxylic acid (50) as the most attractive of all the screened compounds. The X-ray cocrystal structure of 50 bound on PPARγ revealed that the key hydrogen bond interactions, which are not related to the activation function 2 (AF-2) site, are different from those of the full agonist. Compound 50 showed typical PPARγ partial agonist properties in the PPARγ-GAL4 functional assay and weaker differentiation of adipocytes in 3T3-L1 cells than observed with rosiglitazone. Furthermore, 50 displayed comparable antidiabetic efficacy with rosiglitazone in db/db mice, although its potency is 10-fold weaker than that of rosiglitazone.